Skip to Primary Navigation

China eyes total dominance of pharma and biotech supply chains

New report warns Beijing’s growing influence across virtually every stage of the biotech supply chain could create vulnerabilities for the US.

Article label: Quick Read

China’s efforts to control the entire pharmaceutical supply chain, from drug manufacturing to novel treatment discovery, are the subject of a new report from the National Security Commission on Emerging Biotechnology (NSCEB).

The bipartisan, congressionally mandated commission studies how advances in biotechnology affect US national security, economic competitiveness, and strategic

Get full access, free for a month

Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

What’s included:

  • Every new article, plus our 6,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience